End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.59 USD | -.--% | +2.93% | -10.44% |
Mar. 21 | Cibus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 21 | Transcript : Cibus, Inc., Q4 2023 Earnings Call, Mar 21, 2024 |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.44% | 369M | D+ | ||
+8.33% | 217B | B | ||
+6.72% | 183B | B- | ||
+10.18% | 131B | B- | ||
+24.91% | 106B | A- | ||
-0.95% | 62.16B | A- | ||
+10.56% | 51.02B | B+ | ||
+4.81% | 50.89B | B+ | ||
-0.24% | 40.16B | A | ||
+1.22% | 34.79B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
- Stock Market
- Equities
- CLXT Stock
- Ratings CALYXTPAR